» Articles » PMID: 33739257

Paediatric Tuberculosis During Universal and Selective Calmette-Guérin Vaccination Policy: a Nationwide Population-based Retrospective Study, Finland, 1995-2015

Overview
Journal Euro Surveill
Date 2021 Mar 19
PMID 33739257
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

IntroductionIn 2006, the Calmette-Guérin (BCG) vaccination policy in Finland changed from universal to selective.AimWe assessed the impact of the policy change on tuberculosis (TB) morbidity in children under 5 years and epidemiological trends of paediatric TB in Finland.MethodsWe conducted a nationwide, population-based, retrospective registry study of all newly diagnosed active TB cases younger than 15 years in Finland from 1995 to 2015 by linking data from the National Infectious Diseases Register, Finnish Care Register for Health Care, medical patient records and Finnish Population Information System. We compared the TB incidence rate ratio of under 5 year-olds with universal and selective BCG vaccinations with a Poisson log-linear model and analysed incidence trends among those younger than 15 years with a negative binomial model.ResultsWe identified 139 paediatric TB cases: 50 native (including 24 second-generation migrants) and 89 foreign-born children. The TB rate of under 5 year-olds remained stable after changing to selective BCG vaccination (incidence rate ratio (IRR): 1.3; 95% confidence interval (CI): 0.7-2.3). TB rate in the native population under 15 years increased slightly (IRR = 1.06; 95% CI: 1.01-1.11).DiscussionPaediatric TB cases in Finland were concentrated in families with migrant background from high-TB incidence countries. The native TB morbidity in under 5-year-olds did not increase after the BCG policy revision, suggesting that selective vaccinations can prevent TB in the most vulnerable age group in low-incidence settings. Second-generation migrants under 15 years in Finland with high TB risk are probably increasing.

Citing Articles

World Tuberculosis Day 2021: keeping an eye on the 2030 target.

Euro Surveill. 2021; 26(11).

PMID: 33739253 PMC: 7976384. DOI: 10.2807/1560-7917.ES.2021.26.11.2103181.

References
1.
Trnka L, Dankova D, Svandova E . Six years' experience with the discontinuation of BCG vaccination. 2. Cost and benefit of mass BCG vaccination. Tuber Lung Dis. 1993; 74(4):288-92. DOI: 10.1016/0962-8479(93)90056-4. View

2.
Faust L, Schreiber Y, Bocking N . A systematic review of BCG vaccination policies among high-risk groups in low TB-burden countries: implications for vaccination strategy in Canadian indigenous communities. BMC Public Health. 2019; 19(1):1504. PMC: 6849173. DOI: 10.1186/s12889-019-7868-9. View

3.
Kontturi A, Soini H, Ollgren J, Salo E . Increase in Childhood Nontuberculous Mycobacterial Infections After Bacille Calmette-Guérin Coverage Drop: A Nationwide, Population-Based Retrospective Study, Finland, 1995-2016. Clin Infect Dis. 2018; 67(8):1256-1261. DOI: 10.1093/cid/ciy241. View

4.
Marx F, Fiebig L, Hauer B, Brodhun B, Glaser-Paschke G, Magdorf K . Higher Rate of Tuberculosis in Second Generation Migrants Compared to Native Residents in a Metropolitan Setting in Western Europe. PLoS One. 2015; 10(6):e0119693. PMC: 4465484. DOI: 10.1371/journal.pone.0119693. View

5.
Morales-Garcia C, Rodrigo T, Garcia-Clemente M, Munoz A, Bermudez P, Casas F . Factors associated with unreported tuberculosis cases in Spanish hospitals. BMC Infect Dis. 2015; 15:295. PMC: 4518602. DOI: 10.1186/s12879-015-1047-0. View